Cilostazol and several of its metabolites are inhibitors of phosphodiesterase III. Several drugs with this pharmacologic effect have caused decreased survival compared to placebo in patients with class III-IV congestive heart failure. PLETAL is contraindicated in patients with congestive heart failure of any severity.
PLETAL (cilostazol) is a quinolinone derivative that inhibits cellular phosphodiesterase (more specific for phosphodiesterase III).
PLETAL is indicated for the reduction of symptoms of intermittent claudication, as indicated by an increased walking distance.
Published Studies Related to Pletal (Cilostazol)
Cilostazol for intermittent claudication. 
CONCLUSIONS: Cilostazol has been shown to be of benefit in improving
Platelet inhibition by adjunctive cilostazol versus high maintenance-dose clopidogrel in patients with acute myocardial infarction according to cytochrome P450 2C19 genotype. [2011.04]
OBJECTIVES: The aim of this study was to assess the degree of platelet inhibition by adjunctive cilostazol in patients with acute myocardial infarction (AMI) according to hepatic cytochrome P450 2C19 (CYP2C19) genotype. BACKGROUND: Although adjunctive cilostazol intensifies platelet inhibition in AMI patients, it is not established whether this regimen can be free from the effect of CYP2C19 loss-of-function variants (*2/*3)... CONCLUSIONS: Compared with high-MD clopidogrel, adjunctive cilostazol significantly enhances platelet inhibition and reduces the rate of HPR, especially in AMI patients with CYP2C19 loss-of-function variants. (Adjunctive Cilostazol Versus High Maintenance-Dose Clopidogrel in Acute Myocardial Infarction (AMI) Patients According to CYP2C19 Polymorphism [ACCELAMI2C19]; NCT00915733). Copyright (c) 2011 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.
Cilostazol attenuates on-treatment platelet reactivity in patients with CYP2C19 loss of function alleles receiving dual antiplatelet therapy: a genetic substudy of the CILON-T randomised controlled trial. [2011.04]
OBJECTIVE: To evaluate whether the addition of cilostazol to dual antiplatelet therapy (DAT, aspirin plus clopidogrel) can attenuate clopidogrel on-treatment platelet reactivity (OPR) in patients with the CYP2C19 loss-of-function (LOF) allele... CONCLUSION: TAT significantly reduced OPR compared with DAT in carriers of the CYP2C19 LOF allele, but not in non-carriers. These data suggest that the addition of cilostazol to DAT may be a good strategy to attenuate CYP2C19 LOF-related high OPR.
A randomized, double-blind, multicenter comparison study of triple antiplatelet therapy with dual antiplatelet therapy to reduce restenosis after drug-eluting stent implantation in long coronary lesions: results from the DECLARE-LONG II (Drug-Eluting Stenting Followed by Cilostazol Treatment Reduces Late Restenosis in Patients with Long Coronary Lesions) trial. [2011.03.15]
OBJECTIVES: The purpose of this study was to determine whether cilostazol reduces intimal hyperplasia in patients undergoing long zotarolimus-eluting stent implantation (stent length: >/= 30 mm) for native long coronary lesions (length: >/= 25 mm). BACKGROUND: Restenosis after drug-eluting stent implantation remains a significant clinical problem in long coronary lesions... CONCLUSIONS: Patients receiving triple antiplatelet therapy after long zotarolimus-eluting stent implantation had decreased extent of late luminal loss, percent intimal hyperplasia volume, and angiographic restenosis, resulting in a reduced risk of 12-month target lesion revascularization compared with patients receiving dual antiplatelet therapy. (Triple Versus Dual Antiplatelet Therapy after ABT578-Eluting Stent; NCT00589927). Copyright (c) 2011 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.
Multicenter randomized trial evaluating the efficacy of cilostazol on ischemic vascular complications after drug-eluting stent implantation for coronary heart disease: results of the CILON-T (influence of CILostazol-based triple antiplatelet therapy ON ischemic complication after drug-eluting stenT implantation) trial. [2011.01.18]
OBJECTIVES: We aimed to test whether cilostazol has beneficial effects in the real-world patients treated with intracoronary drug-eluting stents (DES). BACKGROUND: The addition of cilostazol on the conventional dual antiplatelet therapy has been reported to reduce platelet reactivity and to improve clinical outcomes after percutaneous coronary intervention in previous studies... CONCLUSIONS: Despite the greater reduction of platelet reactivity by addition of cilostazol to conventional DAT, TAT did not show superiority in reducing the composite of adverse cardiovascular outcomes after DES implantation. (The Efficacy of CILostazol ON Ischemic Complications After DES Implantation [CILON-T]; NCT00776828). Copyright A(c) 2011 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.
Clinical Trials Related to Pletal (Cilostazol)
Fasted Bioavailability Study of Cilostazol Tablets, 100 mg [Completed]
Fasted Bioavailability Study of Cilostazol Tablets, 50mg [Completed]
Evaluation of Cilostazol in Combination With L-Carnitine [Completed]
The purpose of this study is to see how safe and effective L carnitine taken with cilostazol
is compared to placebo taken with cilostazol for people with intermittent claudication. A
second purpose of the study is to see if L-carnitine is absorbed into the blood stream.
Cilostazol and Its Effects on Resumption of Meiosis in the Human Ovary [Completed]
Combined oral contraceptive pills (COCs) are the most commonly used hormonal form of birth
control in the United States with at least 87% of women of reproductive age reporting oral
contraceptive use at some point in their lives (9). Despite their frequent use, the six and
twelve month discontinuation rates for oral contraceptive pills are 31 and 47 % respectively
(17), with common reasons for discontinuation attributed to the side effects of abnormal
bleeding, headache, and weight gain.
Additionally, COCs are contraindicated in certain groups of women as outlined by The Centers
for Disease Control Medical Eligibility Criteria (11). Given the high prevalence of oral
contraceptive users who commonly discontinue use secondary to side effects or who are not
eligible for use as a result of underlying health conditions, the development of novel oral
non-hormonal methods that are equally effective at pregnancy prevention are warranted.
This current study aims to evaluate the effect of an FDA approved drug, Cilostazol, on human
oocyte maturation. Such a study has not been conducted to date. If Cilostazol demonstrates
an ability in humans to affect resumption of meiosis, then this non-hormonal agent could be
uses as a possible contraceptive agent in the future. This knowledge would have profound
reproductive health implications.
The investigators propose that women undergoing treatment with the FDA approved dose of
100mg PO every 12 hours of Cilostazol will demonstrate an impairment of egg maturation in
comparison to paired historic controls following ovarian follicle stimulation.
Cilostazol After Lower Extremity Arterial Revascularization Trial [Not yet recruiting]
Ten patients will be recruited to CLEAR. Five will be randomized to the treatment arm
(Cilostazol) and five will be randomized to the control group. Patients randomized to the
treatment arm will receive Cilostazol for 90 days. The primary purpose of this study is to
collect quality of life data on patients undergoing peripheral revascularization in order to
determine the sample size required to adequately power a trial of Cilostazol versus usual
care without Cilostazol and its effect on quality of life.
Reports of Suspected Pletal (Cilostazol) Side Effects
Interstitial Lung Disease (12),
Cerebral Infarction (11),
Condition Aggravated (8),
Cerebral Haemorrhage (7),
Renal Failure Acute (7),
Hepatic Function Abnormal (6), more >>
Page last updated: 2015-08-10